宫颈癌同步放化疗中期FDG-PET/CT代谢变化与预后相关
单中心前瞻性临床试验纳入30例IB1-IVB期宫颈癌患者,在同步顺铂放化疗前及30-36 Gy时行FDG-PET/CT,分析代谢参数与生存结局的关系。中位随访24个月,2年OS为68%,DFS为44%;同步放化疗中期TLG与OS、DFS及淋巴结复发显著相关,而基线与中期参数变化多与结局无关。
要点
- 同步放化疗中期FDG-PET/CT的TLG与OS、DFS及淋巴结复发相关。
- 中期TLG对OS的HR为1.35(95%CI 1.15-1.55,P=.001)。
- 基线与中期代谢参数变化除平均SUV相对变化与宫颈复发相关外,多与结局无关。
核心结论
- 在高危宫颈癌接受同步放化疗和近距离治疗的患者中,同步放化疗中期FDG-PET/CT的TLG和代谢肿瘤体积与OS相关,可能为选择性治疗强化提供早期信号。
研究设计与样本
- 单中心前瞻性临床试验纳入30例FIGO IB1-IVB期宫颈癌女性,接受顺铂为基础的同步放化疗和近距离治疗。
- 在放化疗前及30至36 Gy时行FDG-PET/CT,记录原发肿瘤和临床受累淋巴结的最大及平均SUV、代谢肿瘤体积和TLG。
主要发现
- 中位随访24个月,2年OS为68%(95%CI 51%-85%),DFS为44%(95%CI 26%-63%),DM为42%(95%CI 23%-59%),NR为14%(95%CI 4%-30%),CR为10%(95%CI 2%-24%)。
- 同步放化疗中期TLG与OS(HR 1.35;95%CI 1.15-1.55;P=.001)、DFS(HR 1.19;95%CI 1.04-1.34;P=.018)和NR(HR 1.25;95%CI 1.10-1.40;P=.002)相关。
- 单因素分析中,除平均SUV相对变化与CR相关(P=.004)外,基线与中期FDG-PET/CT参数间的绝对或相对变化均与疾病结局无关。
关键数值与推荐
- 同步放化疗中期TLG与OS、DFS和NR显著相关,HR分别为1.35、1.19和1.25。
- 平均SUV相对变化与CR相关,P=.004。
临床怎么用
- 同步放化疗中期FDG-PET/CT的TLG和代谢肿瘤体积可提供预后信息,或有助于识别适合剂量递增或辅助化疗等选择性治疗强化的患者。
局限性
- 研究为单中心前瞻性临床试验,样本量仅30例,随访时间有限,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess whether radiographic and metabolic changes on midchemoradiation therapy (CRT) fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for cervical cancer predict outcome. METHODS AND MATERIALS: Women with International Federation of Gynecology and Obstetrics stage IB1-IVB cervical cancer treated with concurrent cisplatin-based CRT and brachytherapy were enrolled on a single-institution prospective clinical trial; FDG-PET/CT was obtained before CRT and at 30 to 36 Gy. Max and mean standard uptake values, metabolic tumor volume, and total lesion glycolysis (TLG) for the primary tumor and clinically involved lymph nodes from the pre-CRT and intra-CRT FDG-PET/CT were recorded. Clinical endpoints analyzed include overall survival (OS), disease-free survival (DFS), and rates of cervical recurrence (CR), nodal recurrence (NR), and distant metastasis (DM). FDG-PET/CT variables and other prognostic factors associated with clinical endpoints were identified via univariate Cox proportional hazards modeling and competing risk analysis. RESULTS: Thirty women were enrolled from 2012 to 2016. After a median follow-up of 24 months, 2-year rates of OS, DFS, DM, NR, and CR were 68% (95% confidence interval [CI], 51%-85%), 44% (95% CI, 26%-63%), 42% (95% CI, 23%-59%), 14% (95% CI, 4%-30%), and 10% (95% CI, 2%-24%), respectively. Intra-PET metrics and TLG across all PET scans were most consistently associated with OS, DFS, DM, and NR on univariate analysis. Intra-CRT TLG was associated with OS (hazard ratio [HR] 1.35; 95% CI, 1.15-1.55; P = .001), DFS (HR 1.19; 95% CI, 1.04-1.34; P = .018), and NR (HR 1.25; 95% CI, 1.10-1.40; P = .002). No absolute or relative changes between parameters of baseline and mid-CRT FDG-PET/CT were associated with disease outcomes on univariate analysis, with the exception of relative change in mean standard uptake values and CR (P = .004). CONCLUSIONS: In this group of patients with high-risk cervical cancer treated with CRT and brachytherapy, TLG and metabolic tumor volume on intra-CRT FDG-PET/CT was associated with OS. These metrics may provide an early signal for selective treatment intensification with either dose escalation or adjuvant chemotherapy.
引用
- Carpenter DJ, Jacobs CD, Wong TZ, et al. Changes on Midchemoradiation Therapy Fluorodeoxyglucose Positron Emission Tomography for Cervical Cancer Are Associated with Prognosis. Int J Radiat Oncol Biol Phys. 2019. PMID: 31254659. doi:10.1016/j.ijrobp.2019.06.2506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。